Ruxolitinib
Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
| Supplier | Selleck Chemicals |
|---|---|
| Product # | S1378 |
| Sku # | S1378-100mg |
| Pricing | 100mg, $589.00 |
Citations for this product:
-
bioRxiv - Microbiology 2020Quote: Ruxolotinib (INCB018424) was from Selleck Chemicals (#S1378) and Baricitinib phosphate from Fisher Scientific (#50-201-3519).
-
bioRxiv - Systems Biology 2021Quote: ... 10 μM ruxolitinib (Selleck Chemicals #S1378) and Nuclight Rapid Red Dye (Essen Bioscience #4717 ...
-
bioRxiv - Molecular Biology 2023Quote: ... was ordered from PBL Assay Science (Piscataway, NJ, USA) and Ruxolitinib (IFNAR inhibitor, dissolved in DMSO, #S1378) from Selleck Chemicals GmbH (Absource Diagnostics ...
-
Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer CellsbioRxiv - Cancer Biology 2023Quote: ... JAK1/2 inhibitor Ruxolitinib (Ruxo, Selleck Chemical LLC S13785MG), TBK1 inhibitor GSK8612 (GSK ...